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SUMMARY
Individuals developing an HIV seroconversion illness may experience rapid disease progression.
Information on seroconversion illness is rarely collected in most cohort studies; thus the aim of
this study was to assess the value of the HIV test interval (the time between last negative and
®rst positive HIV tests) as a proxy for seroconversion illness. Among 8229 seroconverters, test
intervals ranged from 0±5282 days, and varied by gender, risk group, age and calendar year of
seroconversion. Those with intervals %31 days had an increased hazard of AIDS (RH 1±42,
P¯0±07), which was reduced slightly after adjusting for baseline factors, calendar year of
follow-up, treatment and the declining CD4 count, but there was no eﬀect on survival. Thus, it
appears that if information on acute seroconversion illness is not available, then analyses of
progression to AIDS in seroconverter studies could use a short test interval as a proxy
measure.
INTRODUCTION
Many individuals may develop some type of clinical
manifestation at the time of primary infection with
HIV [1]. Typically, seroconversion `illness' resembles
a ¯u-like illness and can include fever, malaise,
headaches, night sweats, nausea and diarrhoea [2±6].
The presence, severity and duration of a clinically
recognized seroconversion illness is associated with
more rapid progression to AIDS and shorter survival
[5, 7±13]. The high HIV RNA levels seen at the time
of primary infection [14, 15] and the subsequent rapid
rate of CD4 loss [11] in these individuals may suggest
a mechanism for this eﬀect.
Cohort studies of HIV seroconverters (i.e. indi-
vidualswithknowndatesofHIVnegativeandpositive
test results) often select individuals for inclusion
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retrospectively. In such cases, information on symp-
tomatic primary infection may not always be available
in patient notes: Where this information is available,
it is likely to be subject to recall bias. Even
prospectively followed cohorts of HIV negative
individuals may not necessarily detect all sero-
conversion illnesses due to the wide spectrum of
clinical events that may be manifest [16]. Thus, the
impact of symptomatic primary infection on HIV-1
disease progression is often diﬃcult to assess or
control for in such studies.
Many cohort studies estimate the time of sero-
conversion as the mid-point between the dates of the
last negative and ®rst positive HIV test result (the
`mid-point method') [17]. The development of a
seroconversion illness may prompt some individuals
to present for medical care and, if seroconversion
illnesses is suspected, the clinician may request an
HIV test following this presentation. If the individual
is still in the process of seroconverting to HIV, then
this ®rst test may be negative and clinicians are likely92 CASCADE European Collaborative Project
to follow this up with a repeat test, which will be
positive, a few weeks later. Thus, these individuals are
likely to have very short intervals between their last
negative and ®rst positive tests (the HIV test interval).
Alternatively, the individual may have already sero-
converted at the time of the ®rst test, which will be
positive. In this case, the test interval, depending on
the regularity of HIV testing, is still likely to be
shorter than that of patients without a seroconversion
illness in whom the ®rst positive test is likely to occur
later in time. Thus, measurement of the length of the
HIV test interval may provide a simple means to
assess the impact of symptomatic primary infection
on HIV disease progression in cohorts where this
information is not collected prospectively.
The aim of this study is to describe HIV test
intervals in a large, multi-cohort study of HIV
seroconverters. In particular, we wished to describe
the factors which are related to the HIV test interval,
and to assess the relationship between a very short test
interval,progression to AIDS and death and immuno-
logical decline.
METHODS
The CASCADE Study
The CASCADE Study has been described fully
elsewhere[18].Brie¯y,thestudyaimstobringtogether
European and Australian data and expertise to
address questions on natural history which cannot be
adequately addressed through single studies. Cur-
rently, 19 cohorts participate in the collaboration,
which includes a total of 8729 HIV seroconverters.
Information on the estimated seroconversion date
(estimateddate, dates of ®rst positiveand last negative
HIV tests, method of estimating seroconversion date,
and of verifying the date of the last HIV negative test
result) was collected for each individual in the study.
The analysis in this paper is based on 8229 individuals
from the CASCADE data set in whom dates of last
negative and ®rst positive HIV tests were both
available.
Statistical methods
The HIV test interval was de®ned as the time interval
between the dates of the last negative and ®rst positive
HIV test results for each individual. The test intervals
were compared in diﬀerent demographic groups using
unpaired t-tests and ANOVA methods after taking a
log transformation to normalize the values and to
obtain approximately equal variances in the groups.
Multiple regression analysis was performed on the
transformed data to assess the independent eﬀects of
each of the factors on the length of the test interval.
The impact of a short test interval on progression to
AIDS and death were assessed using the Cox
proportional hazards regression model [19]. Short test
intervals were de®ned to be 31 days or less. Time to
AIDS and survival were calculated from the estimated
date of seroconversion until the date of developing
AIDS or death, as appropriate. In individuals who
remained AIDS-free at the end of the study, or who
had not died, follow-up was right-censored. The
method of right-censoring was cohort-speci®c, ac-
cording to individual cohort protocols. All models
were strati®ed by study cohort and, as follow-up on
some individuals did not begin until some time after
seroconversion, allowed for late entry into the cohort
(`left truncation').
Relative hazards, 95% con®dence intervals and P-
values are presented unadjusted and adjusted for
baseline demographic factors (age at seroconversion,
sex, exposure group, ethnicity, calendar year of
seroconversion and the method by which the last
negativetest was determined),calendar year of follow-
up (!1991, 1991±2, 1993±4, 1995±6, 1997 onwards)
and antiretroviral treatment (dates of starting mono-
therapy, double therapy, triple therapy excluding
protease inhibitors, triple therapy including protease
inhibitors). The latter two variables were included as
time-updated covariates in the models. All other
variables were considered ®xed at baseline.
In order to assess whether any eﬀect of a short test
interval could be explained by more rapid CD4 loss in
individuals with short test intervals, two additional
sets of analyses were performed. Firstly, the re-
lationship between a short test interval and the time to
a CD4 count !200 cells}mm$ was performed in those
individuals whose baseline CD4 count was above
200 cells}mm$ using the Cox proportional hazards
model. As the CD4 count is known to drop at the time
of seroconversion, before increasing to near pre-
seroconversion levels over the ®rst 6 months of
infection or so, the baseline CD4 count for this
analysis was de®ned as the ®rst CD4 count measured
at least 9 months after the estimated date of
seroconversion. For this analysis, follow-up was right-
censored 6 months after the last available CD4 count,
to ensure that individuals with infrequent CD4
monitoring could not bias the results. Secondly, the93 HIV disease progression
Table 1. Demographic details of 8229 indiiduals included in study, and of reduced data set used for
proportional hazards regression analysis examining progression to AIDS, death and a CD4 count
!200 cells}mm$
Full data set
(n¯8229)
Reduced data set*
(n¯6451)
Age at !20 475 (5±8%) 310 (4±8%)
seroconversion 20±29 4203 (51±1%) 3338 (51±7%)
(years) 30±39 2363 (28±7%) 1899 (29±4%)
40±49 853 (10±4%) 660 (10±2%)
&50 335 (4±1%) 244 (3±8%)
Sex Male 6536 (79±4%) 5071 (78±6%)
Female 1693 (20±6%) 1380 (21±4%)
Exposure group Homo}bisexual 4196 (51±0%) 3414 (52±9%)
Injecting drug users 2073 (25±2%) 1582 (24±5%)
Heterosexual 1517 (18±4%) 1290 (20±0%)
Haemophilia 248 (3±0%) 0 (®)
Other}not stated 195 (2±4%) 165 (2±6%)
Ethnic group White 3400 (41±3%) 2097 (32±5%)
Black 152 (1±8%) 126 (2±0%)
Other 112 (1±4%) 112 (1±7%)
Not stated 4565 (55±5%) 4116 (63±8%)
Date of last Veri®ed by lab}clinic 5845 (71±0%) 4492 (69±6%)
negative HIV test Reported by subject 2384 (29±0%) 1959 (30±4%)
Determination of Midpoint method 7176 (87±2%) 6351 (98±4%)
seroconversion
date
Laboratory evidence
of seroconversion
100 (1±2%) 100 (1±6%)
Evidence of
symptomatic
infection from notes
28 (0±3%) 0 (Ð)
Other 925 (11±2%) 0 (Ð)
Calendar year of %1985 894 (10±9%) 522 (8±1%)
seroconversion 1986±7 1170 (14±2%) 936 (14±5%)
1988±9 1471 (17±9%) 1104 (17±1%)
1990±1 1423 (17±3%) 1156 (17±9%)
1992±3 1344 (16±3%) 1138 (17±6%)
1994±5 1125 (13±7%) 941 (14±6%)
1996±8 802 (9±7%) 654 (10±1%)
* Described in Methods section.
models for progression to AIDS and death were
repeated adjusting for the changing CD4 count as a
time-updated covariate (modelled on the log"! scale).
All analyses were performed using the SAS software
package [17].
For all progression analyses, individuals were only
included if their date of seroconversion had been
estimated using the mid-point method or on the basis
of laboratory evidence of seroconversion. Other
individuals were excluded from the analysis, as
anecdotal evidence suggested that in many cohorts
notes would be searched for other evidence of
seroconversion (i.e. symptoms, sudden drop in CD4
count) only when the test interval was particularly
long, in order to provide a more accurate estimate of
the date of seroconversion. In addition, haemophilic
men (who were all infected prior to 1985) and those
whose ®rst positive HIV test was prior to 1985 (which
must have been obtained retrospectively, as an HIV
test did not become available until 1985), were also
excluded from progression analyses as it was felt that
the length of the test interval in these individuals was
more likely to relate to clinic policy on the collection
and storage of blood samples at the time, than to
presentation because of symptomatic primary in-
fection. Finally, patients from three centres who had
not provided follow-up CD4 data for all patients,
were excluded. Thus, the progression analysis was94 CASCADE European Collaborative Project
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Fig. 1. Distribution of HIV test intervals among 8229 individuals from the CASCADE study.
based on 6451 individuals from the full data set
(78±4%).
A number of sensitivity analyses were performed.
Firstly, the analysis was repeated de®ning a short test
interval as less than 45 days. Secondly, the analysis
was repeated after excluding those patients whose last
negative test result had not been veri®ed by the
laboratory and was based on subject report only.
RESULTS
Details of the 8229 individuals with both last negative
and ®rst positive HIV test results, and of the 6451
individuals included in the progression analyses are
shown in Table 1. The majority of individuals in the
study were male, reported a sexual risk for HIV
infection and were aged between 20 and 40 years at
thetimeofseroconversion.Ofthoseinwhomethnicity
was recorded, the majority were white, although many
cohorts did not collect this information. In 71% of
individuals in the whole cohort, the date of the last
negative test result had been veri®ed by the laboratory
or clinic and the seroconversion date was estimated
using the mid-point method in 87% of individuals.
Seroconversion was estimated to have occurred
between 1979 and 1998, with a similar proportion of
individuals seroconverting in each calendar period.
With the exception of the exclusion of haemophilic
men, the demographic details of the reduced popu-
lation used in the progression analyses were similar to
those of the whole population.
Test intervals among the 8229 seroconverters
ranged from 0±5282 days (geometric mean 283 days)
and are shown in Figure 1. It should be noted that
some of the individual cohort studies had placed
eligibility restrictions on the length of test interval that
was permissible in a seroconverter. Thus, this ®gure is
likely to underestimate the distribution of test
intervals in all individuals with a prior negative test.
Geometric mean test intervals (and 95% con®dence
intervals [CI]) for subgroups of the study population
are shown in Table 2. The test interval tended to get
progressively shorter with increasing age at sero-
conversion (P¯0±0005). Haemophilic men had
longest test intervals and those from other}not stated
exposure groups the shortest (P¯0±0001). Black
individuals also had longer test intervals than those of
other ethinicities (P¯0±02). Those whose negative
date was veri®ed by the laboratory or clinic had
shorter test intervals, on average, than those whose
negative date had been reported by the subject only
(P¯0±0001). In addition, those in whom there was
laboratory evidence of seroconversion had particu-
larly short test intervals and those whose sero-
conversion date had been based on knowledge of a
putative seroconversion illness had long test intervals
(P¯0±0001). Finally, there were diﬀerences in the
length of test interval according to calendar year of95 HIV disease progression
Table 2. Relationships between baseline factors and HIV test interal ± uniariate results
Geometric
mean (days)
95% Con®dence
interval P-value*
Age at seroconversion !20 296 (256±342)
(years) 20±29 295 (282±308)
30±39 284 (265±304)
40±49 257 (224±295)
&50 200 (145±275) 0±0005
Sex Male 283 (272±294)
Female 282 (258±308) 0±93
Exposure group Homo}bisexual 265 (253±278)
Injecting drug
users
306 (289±324)
Heterosexual 306 (279±335)
Haemophilia 626 (545±720)
Other}not stated 97 (55±173) 0±0001
Ethnic group White 279 (262±297)
Black 413 (337±507)
Other 347 (246±490)
Not stated 281 (269±274) 0±02
How was negative date
determined?
Veri®ed by lab}
clinic
210 (201±220)
Reported by
subject
585 (558±613) 0±0001
How was sc date
determined?
Midpoint method 304 (294±315)
Lab evidence of
seroconversion
31 (15±65)
Seroconversion
illness
1171 (849±1616)
Other 194 (169±223) 0±0001
Calendar year of sc %1985 222 (189±250)
1986±7 235 (219±253)
1988±9 305 (284±338)
1990±1 347 (323±373)
1992±3 345 (319±373)
1994±5 306 (279±336)
1996±8 188 (162±217) 0±0001
* From ANOVA or unpaired t-tests, after log transformation, as appropriate.
seroconversion (P¯0±0001), although this eﬀect did
not appear to be linear. In univariable analyses,
gender did not appear to be related to the test interval.
All of the factors remained signi®cantly associated
with the test interval in multivariable analyses (Table
3). In addition, after adjusting for the other factors,
women were found to have a shorter test interval than
men (P¯0±005).
A total of 459 (5±6%) individuals in the whole
cohort, and 342 (5±3%) individuals in the reduced
cohort, had test intervals of %31 days. Treatment
uptake among those with short test intervals and
other individuals was generally similar, although a
slightly higher proportion of those with short test
intervals (43±6%) started monotherapy over follow-
up than those with longer test intervals (32±8%, P!
0±0001). No diﬀerences were seen in the proportion of
individuals starting dual therapy, triple therapy or a
protease inhibitor.
The eﬀect of a short test interval on progression to
AIDS, death and a CD4 count of 200 cells}mm$ is
shown in Table 4. Of the 6451 individuals in the
progression analysis population, 1417 (22±5%) de-
veloped AIDS over follow-up. Before adjusting for
other factors, those with a short test interval had a
42% increased hazard of developing AIDS over96 CASCADE European Collaborative Project
Table 3. Relationships between baseline factors and HIV test interal ± coeﬃcients, 95% con®dence interals
and p-alues from multiple regression model
Estimate
95% Con®dence
interval P-value
Overall estimate of
mean log (test interval)*
1±869 1±781 to 1±957 0±0001
Age at seroconversion (per 10 year
increase in age)
®0±025 ®0±042 to ®0±008 0±004
Sex Male 0 Ð Ð
Female ®0±059 ®0±104 to ®0±015 0±01
Exposure group Homo}bisexual 0 Ð Ð
Injecting drug
users
0±117 0±075 to 0±159 0±0001
Heterosexual 0±025 ®0±023 to 0±074 0±30
Haemophilia 0±711 0±608 to 0±813 0±0001
Other}not stated ®0±356 ®0±454 to ®0±258 0±0001
Ethnic group White 0 Ð Ð
Black 0±162 0±051 to 0±274 0±004
Other 0±127 ®0±001 to 0±255 0±05
Not stated ®0±082 ®0±117 to ®0±046 0±0001
How was negative date
determined?
Veri®ed by lab}
clinic
0Ð Ð
Reported by subject 0±432 0±397 to 0±466 0±0001
How was sc date
determined?
Midpoint method 0 Ð Ð
Lab evidence of
seroconversion
®0±867 1±002 to ®0±732 0±0001
Seroconversion
illness
0±672 0±428 to 0±923 0±0001
Other ®0±193 ®0±247 to ®0±138 0±0001
Calendar year of sc %1985 0 Ð Ð
1986±7 0±144 0±050 to 0±179 0±0001
1988±9 0±225 0±162 to 0±288 0±0001
1990±1 0±223 0±608 to 0±813 0±0001
1992±3 0±200 0±136 to 0±265 0±0001
1994±5 0±114 0±046 to 0±181 0±001
1996±8 ®0±094 ®0±166 to ®0±021 0±01
* The overall estimate of the mean log (test interval) relates to a 20 year-old white male homosexual, infected prior to 1985,
in whom the seroconversion date was based on laboratory evidence of seroconversion and the date of last negative test has
been veri®ed by the laboratory.
follow-up compared to other individuals (P¯0±002).
After adjusting for baseline demographic details,
calendar period of follow-up and treatment uptake,
this relative hazard dropped slightly (relative hazard
[RH] 1±25, P¯0±05). After further adjusting for the
CD4 count as a time-updated covariate, the relative
hazard remained similar (RH 1±30, P¯0±03)
suggesting that this eﬀect of a short test interval could
not be explained by a more rapid rate of CD4 loss in
this group.
A total of 1339 (21±3%) individuals died over
follow-up. In both univariable and multivariable
analyses, there was no signi®cant eﬀect of a short test
interval, although the relative hazard was consistently
above one, suggesting that there may be a small but
non-signi®cant eﬀect of a short test interval on
survival.
Progression to a low CD4 count was considered
only in those individuals whose baseline CD4 count
(measured at least 9 months after seroconversion) was
above 200 cells}mm$. Thus, 5012 individuals were
included in this analysis, of whom 1629 individ-
uals (32±5%) experienced at least one CD4 count
!200 cells}mm$ over follow-up. Again, there were97 HIV disease progression
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no signi®cant eﬀects of a short test interval on
progression rates, either unadjusted or after adjust-
mentfordemographicfactors,calendaryearoffollow-
up and treatment uptake.
One possible explanation for the association be-
tween a short test interval and progression to AIDS is
that if the AIDS event occurred very soon after
seroconversion it may have prompted the patient to
request an HIV test. Thus, the development of AIDS
would lead to a short test interval rather than the
reverse. Seven patients in the cohort (one in the short
test interval group) had a ®rst AIDS diagnosis before
the time of their ®rst positive HIV test. However,
exclusion of these patients had very little eﬀect on the
results of the analysis.
Analyses in which a short interval was de®ned as a
45 days or less (n¯386, 6±1%), gave very similar
results for both AIDS (RH 1±25, 95% CI 1±00 to 1±56,
P¯0±05) and death (RH 1±15, 95% CI 0±91 to 1±46,
P¯0±24). In addition, exclusion of individuals whose
last negative test report had not been veri®ed by
laboratory report, had little eﬀect on the results
(results not shown).
DISCUSSION
The CASCADE study includes almost 8800 infected
individuals with known dates of seroconversion. As
such, this study oﬀers an ideal opportunity to explore
the factors related to the HIV test interval in a group
of individuals who represent all major risk, gender,
ethnicity and age groups. Because of its size, the study
also enables us to consider relationships between
factors which may involve relatively small subgroups
of the population, e.g. those with a short test interval.
The results from this study show large diﬀerences
in the distributions of HIV test intervals between
individuals from diﬀerent risk groups for infection. In
particular, compared to homo}bisexual men, haemo-
philic individuals tend to have very long test intervals,
injecting drug users have slightly longer intervals and
those from other}not stated risk groups tend to have
much shorter test intervals. This is likely, in part, to be
due to the increased awareness of HIV infection in
homo}bisexual men, in whom regular HIV testing is
more common. As haemophilic men were infected
with HIV before a test became available, HIV tests
were retrospectively performed on blood samples
which had generally been stored at regular intervals.
Thus, it may be expected that these test intervals were98 CASCADE European Collaborative Project
less likely to be aﬀected by the presence of a
seroconversion illness. The longer test intervals in
injecting drug users could re¯ect a more chaotic
lifestyle and poorer access to care in this group [21].
Many cohorts did not collect information on eth-
nicity; thus the shorter test intervals in those in whom
ethnicity was unknown should be interpreted cau-
tiously. However, in those in whom ethnicity was
known, black individuals tended to have longer test
intervals than women, possibly re¯ecting poorer
access to care in this group [22].
Test intervals were far longer in those cases where
the last negative test result was reported by the
subject, and in those in whom a history of a putative
seroconversion illness was used to determine the date
of seroconversion. Discussions with the cohorts
involved in the study suggested that as most cohorts
did not collect information on symptomatic infection,
this was only likely to be used to determine sero-
conversion dates when the test interval was very long
and was therefore thought to be particularly in-
accurate. For this reason, these individuals were
excluded from the analyses of progression to AIDS
and death. Interestingly, there was an eﬀect of
calendar year of seroconversion on the test interval.
Compared to those seroconverting before 1985, in
whom the test interval was very short, those who
seroconverted between 1986 and 1993 had signi®-
cantly longer test intervals. Those seroconverting
from 1996 onwards had much shorter test intervals.
Clearly, in order to be recruited to a cohort study as
a seroconverter after 1996, the last negative HIV test
must have taken place relatively recently; because
seroconversion dates were usually estimated using the
midpoint method, anyone whose negative test oc-
curred more than 2 years prior to 1996 would have
had a seroconversion date before 1996. Thus, this
eﬀectively forces the test intervals in this group to be
short.
We found a 42% increase in the hazard of AIDS in
individuals with test intervals %31 days. This eﬀect
was reduced slightly after adjustment for other
demographic factors, calendar year of follow-up and
receipt of antiretroviral treatment, but was not
changed dramatically after adjusting for the changing
CD4 count. Thus, it does not appear that this eﬀect is
explained by a more rapidly declining CD4 count in
those with short test intervals. In addition, there was
no suggestion that these individuals reached a low
CD4 count more rapidly than those with longer test
intervals. However, no eﬀect of a short test interval
was found for death, suggesting that this eﬀect may be
relatively short-lived. Once an individual develops
AIDS, they are likely to receive antiretroviral treat-
ment. Thus, any subsequent eﬀect on death may be
reduced.
One of the most likely explanations for our ®ndings
is that individuals with short test intervals are those
who were prompted to present for medical care
because of symptomatic infection. A number of
studies have reported an association between acute
seroconversion illness and HIV disease progression [5,
7±12]. It has been reported that individuals with
symptomatic primaryinfection,also experience higher
initial HIV-1 RNA levels at the time of seroconversion
[14, 15]. One possible mechanism for an eﬀect of a
short test interval on progression is that individuals
with acute seroconversion may have higher RNA `set-
point' levels which may translate into an increased
risk of disease [23, 24]. Unfortunately, HIV-1 RNA
data is not currently available for the CASCADE
study, and so we cannot address this issue. However,
again, it is likely that such an eﬀect would also be
apparent for survival, thus arguing against such an
eﬀect. A second possible explanation is that some of
the events at the time of symptomatic primary
infection were themselves AIDS-de®ning. Both
Pneumocystis carinii pneumonia and oesophageal
candida have been reported at the time of primary
infection with HIV [25, 26]. Thus, this would clearly
translate into a very rapid progression rate in these
individuals, which probably would not be as apparent
for death. However, in only seven cases, was the date
of ®rst AIDS disease prior to the ®rst positive HIV
test (including one individual with a short test
interval), and exclusion of these individuals did not
aﬀect the results greatly.
Our ®ndings suggest that it may be possible to use
a short test interval as a proxy for seroconversion
illness when performing an analysis of progression to
AIDS. However, clearly a proportion of individuals
with short test intervals are likely to be those who
perceive themselves to be at high risk of infection, e.g.
following unprotected sexual intercourse with a
known HIV-positive partner, but who are asympto-
matic. Furthermore, test intervals for those who
request an HIV test as a result of a seroconversion
illness will only be `short' if they test during the
window of infection (i.e. their ®rst test is negative and
this is followed by a repeat test which is positive).
Individuals whose ®rst test is just after seroconversion
and is positive, will only have a short test interval if,99 HIV disease progression
for some other reason, they had a negative test less
than a month beforehand. Thus, a short test interval
is likely to be an imperfect proxy for seroconversion
illness,althoughitmaybesuﬃcientformostpurposes.
The majority of the individuals included in the
study had their date of seroconversion estimated using
the mid-point method. There is the potential for bias
to be introduced when using the mid-point method to
estimate seroconversion dates if the probability of
infection is not uniformly distributed over the test
interval [17]. Thus, it may be that seroconversion
dates are too early, leading to arti®cially longer times
from seroconversion to AIDS in these patients. This
bias will have least impact in those with the shortest
testintervals;thusit may appearthat theseindividuals
experience more rapid disease progression than those
with longer test intervals. However, such an eﬀect
would also be expected to manifest itself on pro-
gression to death, which is not the case in this study. It
is also likely that the eﬀect would be apparent for test
intervals of diﬀering lengths. In preliminary analyses
(data not shown), there was no diﬀerence in pro-
gression rates according to whether the test interval
was 1±2 months long or 1±2 years. Thus, we do not
believe that this can explain our ®ndings.
In summary, individuals with short test intervals
(%31 days) appear to progress to AIDS more rapidly
than those individuals with longer test intervals. If
information on acute seroconversion illness is not
available, then analyses of progression to AIDS could
adjust for a short test interval as a proxy measure.
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